Long-Term Safety and Effectiveness of MDMA-Assisted Therapy for PTSD
NCT05066282 · MPLONG · Resilient Pharmaceuticals
What it is testing
Summary
Summary as written by the trial’s own sponsor and published on ClinicalTrials.gov API v2. It is the sponsor’s description, reproduced unedited, not an assessment by this site.
What counts as success
Primary outcome measures
Clinician Administered PTSD Scale for DSM-V (CAPS-5) Total Severity Score (actual or imputed) from the main study Baseline and Study Termination to assessment in the current LTFU study
Measured over LTFU IR Assessments at Least 6 Months Since Last Experimental Session in Main Study (Visit 1)
A trial succeeds or fails on its primary outcome, declared in advance. Everything else it reports is secondary by definition.
Who can take part
Eligibility, as published
Where
4 study sites
| Facility | City | Region | Country |
|---|---|---|---|
| USCF | San Francisco | California | United States |
| Dr. Simon Amar Inc | Montreal | Quebec | Canada |
| Beer Yaakov Mental Health Center | Be’er Ya‘aqov | — | Israel |
| Tel Hashomer | Tel Aviv | — | Israel |
On the registry
Contact the trial directly
This site does not enrol anyone and is not involved in this trial. To ask about taking part, use the sponsor’s own contact details on the official registry record, which is also where the most current version of everything above lives.
Before you do, the preparation checklist lists what a site will ask you on a first call and what is worth asking them. It is free and collects nothing.
NCT05066282 on ClinicalTrials.gov →
Last updated in the registry 2024-10-30. Registry records change; this page reflects the data build of 2026-08-25.
Related